Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

Stock Information for Allakos Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Allakos Inc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, HMST, ALLK, OPOF on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc. - ALLK
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Allakos, Inc. (ALLK)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Allakos Inc. Buyout
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, RDFN, ALLK on Behalf of Shareholders
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.